TIDMC4XD
RNS Number : 6492K
C4X Discovery Holdings PLC
12 April 2018
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES
OF ARTICLE 7 OF REGULATION 2014/596/EU.
C4X Discovery Holdings plc
("C4XD", "C4X Discovery" or the "Company")
Interim results for the six months ended 31 January 2018
12 April 2018 - C4X Discovery Holdings plc (AIM: C4XD), a
pioneering drug discovery company, today announces its interim
results for the six months ended 31 January 2018.
Corporate highlights:
Deal update
-- On 29 March 2018, post-period end, C4XD announced a licensing
deal with Indivior worth up to $294 million for C4XD's oral
Orexin-1 receptor antagonist for the treatment of addiction,
receiving $10 million upfront. The treatment of addiction
represents a substantial area of unmet medical need, forecast to be
worth an estimated $13 billion per annum in 2018(1) .
Discovery Engine progress
-- Following the out-licensing of C4XD's IND-ready Orexin-1
programme to Indivior, the Company now has three lead drug
discovery programmes showing in vivo activity, opening up a path to
candidate selection and opportunity to progress to partnering
discussions.
-- C4XD's proprietary drug asset portfolio of ten programmes
across a number of therapeutic areas, including inflammation,
neurodegeneration, immuno-oncology, addiction and diabetes, has
progressed towards revenue generation.
Innovative technologies to advance drug development
-- A new version of the Taxonomy3(R) software was released in
late 2017 which has doubled the analysis speed for gene-gene
interaction and continued investment in the software will result in
C4XD being capable of analysing six disease datasets per annum.
-- C4XD has initiated the creation of a specialised visualiser
("4Sight") to allow the viewing of C4XD's proprietary 4D molecular
data to provide a revolutionary way of viewing and comparing
molecules in a virtual world utilising the latest VR
technology.
-- 4Sight has been chosen as a case study for Immerse UK which
is supporting the UK in becoming the global leader in the
application of immersive technologies.
Financial highlights:
-- Investment in R&D was GBP3.4 million in the six months
ending 31 January 2018, up GBP0.4 million from the GBP3.0 million
in the six months ended 31 January 2017 reflecting progress across
the portfolio.
-- Cash, cash equivalents, short-term investments and deposits
at 31 January 2018 of GBP1.4 million (31 July 2017: GBP2.2 million
and 31 January 2017: GBP6.0 million).
-- Net assets at 31 January 2018 of GBP6.2 million (31 July
2017: GBP10.1 million and 31 January 2017: GBP6.9 million).
Post-period end
-- Post-period end an R&D tax credit of GBP1.7 million and
the upfront payment from Indivior of GBP7.1 million ($10.0 million)
have been received.
Dr Clive Dix, CEO of C4X Discovery, said: "The recent period has
seen C4XD make significant progress towards our goal of becoming
the world's most productive, self-sustaining drug discovery engine.
We have strengthened our portfolio of pre-clinical assets aimed at
meeting the pharma industry's increasing demand for high quality
early-stage drug candidates and now have a number maturing towards
potential out-licensing discussions, with three in particular
gaining momentum and commercial interest. The post period
completion of the deal with Indivior validates our business model
and serves as a solid foundation on which to build towards
additional high-value licensing agreements for our portfolio,
existing and future."
1. Source: GBI Research 2012
Analyst conference call today
Clive Dix (Chief Executive Officer), Brad Hoy (Chief Financial
Officer) and Craig Fox (Chief Scientific Officer) will present the
results at 10:00am BST on 12 April 2018 during a live conference
call and webcast. A copy of the final results presentation will be
released later this morning on the Company's website at
www.c4xdiscovery.com.
Dial-in details are:
Participant local dial-in: +44 (0)330 336 9411
Participant free phone dial-in: 0800 279 7204
Participant code: 2785155
To access the audio webcast, please follow this link.
An audio replay file will be made available shortly afterwards
via the Company website: www.c4xdiscovery.com.
--S-
For further information, please contact:
C4X Discovery Holdings plc
Clive Dix, Chief Executive Officer 07801 865 803
Panmure Gordon (UK) Limited (NOMAD and Broker) 020 7886 2500
Freddy Crossley, Emma Earl (Corporate Finance)
Tom Salvesen (Corporate Broking)
Consilium Strategic Communications
Mary-Jane Elliott, Chris Gardner, Matthew Neal 0203 709 5700
About C4X Discovery
C4X Discovery aims to become the world's most productive drug
discovery engine by exploiting cutting edge technologies to design
and create best-in-class small-molecule candidates targeting a
range of high value therapeutic areas. The company's goal is to
drive returns through early-stage revenue-generating deals with the
pharmaceutical industry.
C4X Discovery has a state-of-the-art suite of proprietary
technologies across the drug discovery process. The company's
innovative DNA-based target identification platform (Taxonomy3(R))
utilises human genetic datasets to identify novel patient-specific
targets leading to greater discovery productivity and increased
probability of clinical success. This is complemented by C4XD's
novel drug design platform which comprises two innovative chemistry
technologies, Conformetrix and Molplex, that combine 4D molecular
shape analyses (based on experimental data) with best-in-class
computational chemistry. This provides new and unprecedented
insight into the behaviour of drug molecules, enabling the
production of potent selective compounds faster and more cost
effectively than the industry standard.
C4X Discovery is advancing its in-house pipeline in
inflammation, neurodegeneration, immuno-oncology, addiction, and
diabetes with a number of new drug candidates identified and
further progress made towards the pre-clinical licensing
discussions. In selecting new targets C4X Discovery will focus on
the high-value disease areas and will continue to maximise value
from opportunistic areas, for example, immuno-oncology, addiction,
and diabetes.
The Company was founded as a spin-out from the University of
Manchester. It has a highly experienced management team and Board
who have delivered significant value creation within the healthcare
sector historically and have enabled C4XD to reach multiple value
inflexion points since IPO. For additional information please go
to: www.c4xdiscovery.com
INTERIM CHAIRMAN AND CEO'S STATEMENT:
We remain committed and confident in our ability to capture the
increasing value associated with pre-clinical licensing deals by
generating a high-value asset portfolio focussed in disease areas
with high partnering interest. Our previously-stated goal, once at
'steady state', remains to produce four or more assets suitable for
partnering each year. We were delighted in keeping to our target of
completing at least one revenue-generating deal by the time of this
interim results statement, by announcing on 29 March 2018 the
completion of the licensing agreement worth up to $294 million with
Indivior for our Orexin-1 programme for the treatment of
addiction.
During the interim period, we have focussed on completing the
work required to successfully deliver the Indivior deal as well as
continuing to build our unique drug discovery engine capabilities
to achieve our aim of becoming the world's most productive,
self-sustaining drug discovery company. Our ongoing disease areas
of focus are inflammation, neurodegeneration, immuno-oncology,
addiction and diabetes.
Discovery Engine and portfolio progress
In addition to completing our first licensing deal, we have made
significant progress growing our discovery portfolio
Key highlights
-- C4XD's proprietary drug asset portfolio of ten programmes
across a number of therapeutic areas including inflammation,
neurodegeneration, immuno-oncology, addiction, and diabetes has
progressed towards revenue generation.
-- Three programmes in particular (NRF-2 activator, IL-17
inhibitor and GPR142 agonist) have made significant progress during
the last six months to a point where commercial interest is gaining
momentum.
o C4XD has designed and discovered novel potent activators of
the NRF-2 pathway, which is important in mediating lung diseases
such as chronic obstructive pulmonary disease ("COPD"), pulmonary
arterial hypertension ("PAH") and other chronic inflammatory
diseases as well as metabolic diseases. COPD represents an area of
substantial unmet medical need and a $41 billion market(1) and,
therefore, oral activators of NRF-2 are the subject of considerable
interest to the pharmaceutical industry. The leader in this field
GSK has filed further patents on their molecules against this
target in the last year and are likely to be close to clinical
development. C4XD's newly identified lead compound has excellent
cell potency in vitro (<200 pM) and significantly increases
NRF-2 activation in the lungs in pre-clinical studies following
oral administration at low dose. C4XD's studies continue to further
optimise the series to enable the selection of a pre-clinical
candidate.
o Our small molecule programme against Interleukin-17 ("IL-17"),
a high value clinically validated target for inflammation and
autoimmune diseases such as psoriasis (estimated to be worth $9
billion per annum(2) ), has identified molecules that can
selectively block IL-17 activity whilst keeping the molecular size
of the molecule in the traditional "drug-like" range. To date, the
identification of orally available small molecules has proved
extremely challenging, but they are highly sought after by the
pharmaceutical industry. Very recently we have identified several
potent inhibitors suitable for oral delivery that have been shown
to block IL-17 induced cytokine release in vivo which is a
significant milestone towards the development of an oral medication
targeting this pathway.
o In late 2016, C4XD was awarded a GBP140k Biomedical Catalyst
feasibility study award from InnovateUK to progress hits for the
GPR142 agonist programme for diabetes. Type-2 diabetes ("T2D")
affects over 420 million people worldwide, creating an enormous
healthcare and socio-economic burden. The GPR142 receptor has been
recently reported to be an exciting new target for the treatment of
T2D with several advantages. Firstly, its activation results in
insulin secretion but only in the presence of high blood sugar
levels, avoiding the life-threatening side effect of low blood
sugar associated with insulin-based therapies. Secondly,
pre-clinical research suggests activation of GPR142 causes
glucagon-like peptide-1 (GLP-1) release, and current GLP-1 based
medicines show significant clinical benefit to diabetes patients by
providing glucose control and induce weight loss. These current
GLP-1 based therapies are injectable and so the development of a
GPR142 agonist could have similar clinical activity but would be
orally administered, avoiding compliance issues. Eli Lilly is the
leader in this area and announced it had initiated a Phase 1
clinical study with its GPR142 candidate in July 2017 with an
extension in diabetes patients that is current recruiting. Analysis
of this patient arm of the study will determine whether the
pre-clinical benefits of a GPR142 agonist translate to the clinic
and should this be positive that will drive significant commercial
interest in this target and C4XD's programme. Very recently several
C4XD lead GPR142 agonists were found to be active after oral
administration in a pre-clinical oral glucose tolerance test
establishing a path to candidate selection.
-- C4XD's proprietary target discovery technology Taxonomy3(R)
has identified multiple novel disease associated genes in
Parkinson's Disease (PD) in addition to the identification of
discrete patient sub-groups that could potentially provide an
opportunity in stratified medicine. During 2017, we extended our
original analysis using a second patient dataset from the US which
replicated the presence of discrete patient sub-groups, resulting
in a grand total of 180 novel genes being discovered that have not
previously been associated with PD. The identification of these new
genetic associations further confirms the power of Taxonomy3(R) to
generate novel genetic insights into diseases with high unmet
medical need. To put these findings into context, at the start of
2017 only 40 PD associated genes were known in the scientific
literature, and in September, Genentech and 23andme published the
results of their collaboration in the scientific journal Nature
Genetics (Nature Genetics 49, 1511-1516, 2017), which identified a
further 17 novel genetic variants representing 32 new PD associated
genes. Informatic analysis of proprietary genes discovered with
Taxonomy3(R), together with known genetic susceptibility genes, has
flagged new pathways relevant to the disease aetiology. We are now
selecting the optimum drug targets from the genes we have
discovered that map to these pathways, to progress these targets to
drug discovery programmes, with the first programme very close to
initiation.
1. Source Visiongain, Asthma and COPD Therapies: World Market
2013-2023.
2. Source: Visiongain, Psoriasis Treatment:World Market
2013-2023.
Technology
Taxonomy3(R) platform development
In the last year C4XD has significantly invested in updating its
Taxonomy3(R) software to enable the goal of being capable of
analysing six disease datasets a year. A new version of the
software was released in late 2017 which has doubled the analysis
speed for gene-gene interaction analysis via refactoring the CPU
code architecture. This will also facilitate a move to GPU analysis
in the future should additional computational speed be required in
the cloud environment.
Conformetrix data platform development including VR (virtual
reality) visualisation
C4XD's novel drug design platform "Conformetrix" determines the
3D shapes of drug molecules from experimental data giving medicinal
chemists new and unprecedented insights into the behaviour and
physical properties of drug molecules. This enables the rapid
design and discovery of better and safer drugs for diseases with
high unmet medical need across broad therapeutic areas. During
2017, C4XD's proprietary database of conformational 3D data
surpassed the milestone of 300 drug molecules providing a rich
resource for new drug design underpinning our unique and
differentiated approach.
One challenge with generating this data is that multiple 3D
shape information is generated for each molecule (a "4D" ensemble
of these individual 3D shapes) and scientific insights for design
can be obtained from this data by comparing similar molecules that
have different biological activity.
Visualising comparisons such as these is difficult with current
molecular software as data of this complexity is proprietary to
C4XD. C4XD has initiated the creation of a specialised visualiser
("4Sight") to allow the viewing of C4XD's proprietary 4D molecular
data to provide a revolutionary way of viewing and comparing
molecules and collaborating with multiple users from both a 2D
desktop environment and in a virtual world utilising the latest VR
technology. C4XD has harnessed the "Unreal Engine" from the
computer gaming firm Epic Games as a technological foundation for
this visualiser. The choice was made to use this engine to provide
a cutting-edge render originally built for the high-end gaming
industry but applied to C4XD's proprietary data. This project has
progressed well with the first release of this platform being
deployed late 2017.
Following the successful deployment of "4Sight", this project
has been chosen as a case study for Immerse UK, which brings
together industry, researchers and research organisations, the
public sector, entrepreneurs, innovators and end users to support
the UK in becoming the global leader in applications of immersive
technologies. This case study can be viewed at
http://www.immerseuk.org/case-study/c4x-discovery/
Financial review
Revenue for the six months ended 31 January 2018 at nil was
lower than the equivalent prior period (six month period ended 31
January 2017: GBP0.1 million) reflecting the successful
discontinuation of fee-for-service agreements. C4XD expects future
revenues to be derived from licensing and other income from
commercial agreements with industry partners relating to C4XD's
pre-clinical drug assets such as that signed with Indivior
post-period and the GBP7.1 million ($10 million) upfront payment
associated with it.
Investment in research and development at GBP3.4 million for the
six months ended 31 January 2018 showed an increase compared to the
equivalent prior period (six month period ended 31 January 2017:
GBP3.0 million), reflecting both increase in activity in final
preparation of Orexin-1 for out-licensing and progress being made
across our in-house pipeline.
At GBP1.2 million, administrative expenses for the six months
ended 31 January 2018 have increased compared to those reported in
the equivalent prior period (six month period ended 31 January
2017: GBP1.0 million) due mainly to increases in expenses related
to commercialization activities.
The net loss for the six months ended 31 January 2018 amounted
to GBP3.7 million or a loss of 7.85 pence per Ordinary Share (six
month period ended 31 January 2017: GBP3.0 million or loss of 8.34
pence per Ordinary Share).
C4XD had net assets at 31 January 2018 of GBP6.2 million (31
July 2017: GBP10.1 million and 31 January 2017: GBP6.9 million) and
cash, cash equivalents, short-term investments and deposits of
GBP1.4 million (31 July 2017: GBP2.2 million and 31 January 2017:
GBP6.0 million). Post-period end an R&D tax credit of GBP1.7
million and the upfront payment from Indivior of GBP7.1 million
($10.0 million) have been received.
Outlook
C4XD's combination of state-of-the-art proprietary technologies,
highly experienced scientific team and industry experience, now
coupled with experience in completing commercial licensing
transactions, uniquely positions the Company to fulfil the
pharmaceutical industry's demand for high quality early-stage drug
candidates. As the Company accelerates towards its goal of becoming
the world's most productive, self-sustaining drug discovery engine,
it aims to build on its commercial experience and to continue
building a portfolio of commercially attractive pre-clinical
assets.
Following the out-licensing of C4XD's Ox-1 programme the Company
now has three lead drug discovery programmes compounds showing in
vivo activity, opening up a path to candidate selection and
opportunity to progress to partnering discussions.
Interim consolidated statement of comprehensive income
For the six months ended 31 January 2018
Six months Six months Year
to to to
31 January 31 January 31 July
2018 2017 2017
(Unaudited) (Unaudited) (Audited)
GBP000 GBP000 GBP000
Notes
Revenue 3 - 78 143
Cost of sales - (2) (3)
Gross profit - 76 140
Research and development
expenses (3,357) (3,013) (6,100)
Administrative expenses (1,177) (951) (2,533)
Operating loss (4,534) (3,888) (8,493)
Finance income 3 1 3
Loss before taxation (4,531) (3,887) (8,490)
Taxation 4 875 850 1,708
Loss for the period
and total comprehensive
loss for the period (3,656) (3,037) (6,782)
============= ============= ==========
Loss per share :
Basic and diluted
loss for the period 5 (7.85)p (8.34)p (16.88)p
============= ============= ==========
Interim consolidated statement of changes in equity
For the six months ended 31 January 2018
Share
Issued based Capital
equity Share payment Merger contribution Revenue
capital premium reserve reserve reserve reserve Total
GBP000 GBP000 GBP000 GBP000 GBP000 GBP000 GBP000
At 1 August
2016 2,350 11,597 110 920 195 (10,867) 4,305
Loss for
the six
months to
31 January
2017 - - - - - (3,037) (3,037)
Issue of
share capital 49 4,951 - - - - 5,000
Expenses
of placing - (285) - - - - (285)
Share-based
payments - - 67 - - - 67
At 31 January
2017 2,399 16,263 177 920 195 (13,904) 6,050
======== ======== ========= ======== ============== ========= ========
Loss for
the six
months to
31 July
2017 - - - - - (3,745) (3,745)
Issue of
share capital 91 6,988 - - - - 7,079
Expenses
of placing - (407) - - - - (407)
Share-based
payments - - 83 - - - 83
At 31 July
2017 2,490 22,844 260 920 195 (17,649) 9,060
====== ======= ==== ==== ==== ========= ========
Loss for
the six
months to
31 January
2018 - - - - - (3,656) (3,656)
Share-based
payments - - 124 - - - 124
At 31 January
2018 2,490 22,844 384 920 195 (21,305) 5,528
====== ======= ==== ==== ==== ========= ========
Interim consolidated statement of financial position
As at 31 January 2018
31 January 31 January 31 July
2018 2017 2017
(Unaudited) (Unaudited) (Audited)
Notes GBP000 GBP000 GBP000
Assets
Non-current assets
Property, plant and
equipment 76 100 90
Intangible assets 503 587 570
Goodwill 1,192 1,192 1,192
1,771 1,879 1,852
------------ ---------------- ----------
Current assets
Trade and other receivables 497 547 548
Income tax asset 2,575 2,250 1,700
Cash and cash equivalents 1,390 2,194 6,031
4,462 4,991 8,279
------------ ---------------- ----------
Total assets 6,233 6,870 10,131
------------ ---------------- ----------
Liabilities
Current liabilities
Trade and other payables (705) (820) (1,071)
(705) (820) (1,071)
------------ ---------------- ----------
Total liabilities (705) (820) (1,071)
------------ ---------------- ----------
Net assets 5,528 6,050 9,060
============ ================ ==========
Capital and reserves
Issued equity capital
6 2,490 2,399 2,490
Share premium 6 22,844 16,263 22,844
Share-based payment
reserve 384 177 260
Merger reserve 920 920 920
Capital contribution
reserve 195 195 195
Revenue reserve (21,305) (13,904) (17,649)
Total equity 5,528 6,050 9,060
============ ================ ==========
Approved by the Board and authorised for issue on 12 April
2018
Brad Hoy
Chief Financial Officer
12 April 2018
Interim consolidated cash flow statement
For the six months ended 31 January 2018
Six months Six months Year
to to to
31 January 31 January 31 July
2018 2017 2017
(Unaudited) (Unaudited) (Audited)
GBP000 GBP000 GBP000
Loss after tax and interest (3,656) (3,037) (6,782)
Adjustments for:
Depreciation of property, plant
and equipment 27 21 44
Amortisation of intangible assets 67 67 135
Share-based payments 124 67 150
Taxation (875) (850) (1,708)
Changes in working capital
Decrease/(increase) in trade
and other receivables 51 (118) (119)
(Decrease)/increase in trade
and other payables (366) 68 392
Decrease in deferred revenue - (40) (83)
Cash outflow from operating
activities (4,628) (3,822) (7,971)
Research and development tax
credit received - - 1,408
Net cash outflow from operating
activities (4,628) (3,822) (6,563)
------------- ------------- ----------
Cash flows from investing activities:
Purchases of property, plant
and equipment (13) (27) (40)
Purchases of intangible fixed
assets - - (51)
Net cash outflow from investing
activities (13) (27) (91)
------------- ------------- ----------
Cash flows from financing activities:
Proceeds from the issue of ordinary
share capital - 5,000 12,049
Expenses of placing - (285) (692)
Net cash inflow from financing
activities - 4,715 11,357
------------- ------------- ----------
(Decrease)/increase in cash
and cash equivalents (4,641) 866 4,703
Cash and cash equivalents at
the start of period 6,031 1,328 1,328
------------- ------------- ----------
Cash, cash equivalents and deposits
at the end of the period 1,390 2,194 6,031
============= ============= ==========
Notes to the interim financial report
For the six months ended 31 January 2018
1. Corporate information
The principal activity of the C4X Discovery Holdings plc is
research and development, a review of which is included in the
Interim Chairman's and CEO's Joint Review.
C4XD is incorporated and domiciled in the United Kingdom and its
registered number is 09134041. The address of the registered office
is Manchester One, 53 Portland Street, Manchester, M1 3LD.
The interim financial information was approved for issue on 12
April 2018.
2. Accounting policies
Basis of preparation
The accounting policies adopted in this interim financial report
are consistent with those followed in the preparation of the
Group's annual report and accounts for the year to 31 July 2017,
except for the following changes:
IFRS15: Revenue From Contracts with Customers has been early
adopted. As the Group has no existing revenue streams, there is no
impact on the numbers presented in this report as a result of
adopting this standard.
The interim financial information for the six months ended 31
January 2018 and 31 January 2017 is unaudited and does not
constitute statutory accounts as defined in the Companies Act 2006.
This interim financial report includes audited comparatives for the
year to 31 July 2017. The 2017 annual report and accounts received
an unqualified audit opinion and has been filed with the Registrar
of Companies.
These interim financial statements have been prepared in
accordance with IAS34 Interim Financial Reporting. They do not
include all the information required for a complete set of IFRS
financial statements. However, selected explanatory notes are
included to explain events and transactions that are significant to
an understanding of the changes in the Group's financial position
and performance since the last annual consolidated financial
statements as at and for the year ended 31 July 2017.
Basis of consolidation
This interim financial report consolidates the financial
statements of C4X Discovery Holdings plc and the entities it
controls (its subsidiaries).
3. Segmental information
Operating segments
At 31 January 2018, 31 July 2017 and 31 January 2017 the Group
operated as one segment, being the provision of new technologies to
improve the drug discovery process for novel small molecule
therapies.
This is the level at which operating results are reviewed by the
chief operating decision maker (i.e. the Chief Executive Officer)
to make decisions about resources, and for which financial
information is available.
All revenues have been generated from continuing operations and
are from external customers.
3. Segmental information (continued)
Operating segments (continued)
Six months Six months Year
to to to
31 January 31 January 31 July
2018 2017 2017
GBP'000 GBP'000 GBP'000
Analysis of revenue
Amounts earned under
joint development agreements - 78 143
------------ ----------- --------
- 78 143
-------------------------------------------- ----------- --------
Geographical information
The Group operates in one main geographic area, which is managed
in the UK. The Group's revenue per geographical segment based on
customer's location, is as follows:
Six months Six months Year to
to to
31 January 31 January 31 July
2018 2017 2017
GBP'000 GBP'000 GBP'000
Analysis of revenue
UK - 78 143
------------ ----------- --------
- 78 143
---------------------------------- ----------- --------
All of the Group's assets are held in the UK and all of its
capital expenditure arises in the UK.
4. Taxation
The tax credit is made up as follows:
Six months Six months Year to
to to
31 January 31 January 31 July
2018 2017 2017
GBP'000 GBP'000 GBP'000
UK corporation tax losses - - -
in the period
Research and development
income tax credit receivable (850) (850) (1,700)
Adjustment in respect
of prior periods (25) - (8)
----------- ----------- --------
(875) (850) (1,708)
----------- ----------- --------
5. Loss per share
31 31
31 January January July
2018 2017 2017
GBP'000 GBP'000 GBP'000
-------------------------------------- ------------- ----------------------- -----------
Loss for the financial period
attributable to equity shareholders (3,656) (3,037) (6,782)
Weighted average number of
shares: No. No. No.
Ordinary shares in issue 46,555,087 36,412,279 40,171,732
Basic loss per share (pence) (7.85)p (8.34)p (16.88)p
-------------------------------------- ------------- ----------------------- -----------
Diluted loss per share has not been presented above as the
effect of share options issued is anti-dilutive.
6. Issued share capital and share premium
Deferred Ordinary Share Deferred Share Total
shares shares capital shares premium
Number Number GBP000 GBP000 GBP000 GBP000
---------- ----------- --------- --------- --------- -------
Ordinary and
deferred shares
as at 31 January
2017 2,025,000 37,398,718 374 2,025 16,263 18,662
------------------- ---------- ----------- --------- --------- --------- -------
Issue of share
capital - 9,156,369 91 - 6,988 7,079
Expenses of
placing - - - - (407) (407)
------------------- ---------- ----------- --------- --------- --------- -------
Ordinary and
deferred shares
as at 31 July
2017 and 31
January 2018 2,025,000 46,555,087 465 2,025 22,844 25,334
------------------- ---------- ----------- --------- --------- --------- -------
7. Interim financial report
A copy of this interim condensed financial report is available
on C4XD's website at www.c4xdiscovery.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
IR GGUWUCUPRPPG
(END) Dow Jones Newswires
April 12, 2018 02:00 ET (06:00 GMT)
C4x Discovery (LSE:C4XD)
Historical Stock Chart
From Jun 2024 to Jul 2024
C4x Discovery (LSE:C4XD)
Historical Stock Chart
From Jul 2023 to Jul 2024
